Skip to content
TrialScanner

NCT02218489

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Phase 2CompletedKALALead

Registry record

Lead sponsor
Kala Pharmaceuticals, Inc.
Conditions
Blepharitis
Primary completion
Dec 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02218489 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02218489: Safety and Efficacy of... | TrialScanner